U.S. markets closed

Emerald Health Therapeutics, Inc. (EMHTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0340-0.0003 (-0.87%)
At close: 01:33PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0343
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0230 - 0.0340
52 Week Range0.0200 - 0.1000
Avg. Volume97,473
Market Cap7.921M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-0.1240
Earnings DateNov 28, 2022 - Dec 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EMHTF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Curaleaf Holdings, Inc.Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 22 states, including the assets from the Cura Select and Grassroots acquisitions. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • Newsfile

    Emerald Health Therapeutics, Inc. Reports 2022 Q2 Results

    Vancouver, British Columbia--(Newsfile Corp. - August 31, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the quarter ended June 30, 2021. Selected Financial Information The financial information presented for the years below was derived from financial statements prepared in accordance with IFRS and is expressed in Canadian dollars.Reported in $000sQ2 2022Q2 2021Total revenue ...

  • Newsfile

    Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience

    Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that on August 25, 2022, the Supreme Court of British Columbia issued a final order approving the Company's previously announced plan of arrangement (the "Arrangement") with Skye Bioscience Inc. ("Skye") (OTCQB: SKYE) and declaring that the Arrangement was procedurally and substantively fair and reasonable. The Arrangement was previous

  • GlobeNewswire

    HYTN Awarded Medical Cannabis Sales Licence Increasing Opportunities at Kelowna Facility

    VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (“HYTN” or the “Company”) (CSE: HYTN) is pleased to announce that its wholly owned subsidiary, HYTN Cannabis Inc., has been awarded a license (the “License”) by Health Canada allowing for the sale of cannabis for medical purposes (with possession). This announcement follows a list of license achievements including a Standard Processing License, Cannabis Research License, an Amendment for Sale of Recreational Can